Tirzepatide alleviates Parkinson's disease in mice at one-third the dose of semaglutide by promoting mitochondrial health | Research

The takeaway

Tirzepatide at one-third the dose of semaglutide equally protected dopaminergic neurons in MPTP-induced PD mice by inhibiting pathological mitochondrial fission (↓Drp1) and promoting mitophagy (↑Pink1/Parkin), with both GLP1R and GIPR downregulated in PD patients.

1/3 dose = equal neuroprotection
Tirzepatide protected PD dopaminergic neurons at one-third semaglutide's dose, suggesting dual GLP-1/GIP agonism provides superior neuroprotection

What the researchers found

GLP1R + GIPR downregulated in PD patient neurons. Tirzepatide (1/3 dose) = semaglutide for TH preservation. ↓Drp1 (pathological fission). ↑Pink1/Parkin/p62 (mitophagy). ↑ATP. Improved mitochondrial ultrastructure. Validated by Drp1 inhibitor + mitophagy activator.

Why it matters

Finding that tirzepatide works at one-third the dose of semaglutide for PD suggests the GIP receptor component provides additional neuroprotection, potentially making dual agonists preferred over mono GLP-1 drugs for neurodegeneration.

How the study worked

GSE238129 transcriptomic analysis (PD patients). MPTP-induced subacute PD mice. Tirzepatide, semaglutide, levodopa comparison. TEM, Western blot, IHC. Drp1 inhibitor + mitophagy activator validation. SY5Y cell CQ + 3-MA validation.

What this study cannot tell us

MPTP model (acute toxin, not progressive PD). Mouse study. In vivo doses may not translate to human equivalents. Short treatment duration.

How to read the evidence

Comprehensive preclinical with human transcriptomic, mouse in vivo, and cell validation. Strong multi-level evidence.

When this study was published

Published in 2025.

The bigger picture

This supports dual GLP-1/GIP agonism as a superior neuroprotective approach for PD. Tirzepatide's dose advantage over semaglutide suggests the GIP receptor contributes meaningfully to brain protection.

Questions still open

Does GIPR activation provide independent neuroprotection?
Would tirzepatide outperform semaglutide in clinical PD trials?
Is the 1/3 dose equivalence maintained in humans?

Common questions

Could tirzepatide treat Parkinson's disease?

This study provides strong evidence it could—and possibly better than semaglutide. At just one-third the dose, tirzepatide equally protected brain cells from PD damage by improving their mitochondria. The fact that both GLP-1 and GIP receptors are reduced in PD patients' brain cells suggests targeting both receptors is the optimal approach.

Why might tirzepatide be better than semaglutide for the brain?

Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide only activates GLP-1. This study found both receptors are reduced in Parkinson's disease brain cells. By targeting both, tirzepatide may provide dual protection—achieving the same brain benefit at one-third the dose.

Read the original research

GLP-1/GIP dual agonist tirzepatide alleviates mice model of Parkinson's disease by promoting mitochondrial homeostasis.

International immunopharmacology, 165, 115443

View on PubMed ↗Publisher’s paper ↗

Citation

Tian, Ruixue; Liu, Kexin; Lai, Hurong; Liao, Caifeng; Li, Jian; Tu, Huaijun. (2025). GLP-1/GIP dual agonist tirzepatide alleviates mice model of Parkinson's disease by promoting mitochondrial homeostasis.. International immunopharmacology, 165, 115443. https://doi.org/10.1016/j.intimp.2025.115443